CLEVELAND, Aug. 25 /PRNewswire/ — ViewRay™, Inc., a
privately held medical device company, has secured $20 million in
Series C financing led by new investor Siemens Venture Capital
(SVC) GmbH and joined by existing investors Aisling Capital,
Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors.
The funding is intended to move the ViewRay system, a unique
image-guided radiation therapy system now in the late stages of
development, through the process of commercialization and placement
in major medical centers.*
The ViewRay system is designed to improve the accuracy of cancer
treatments through a combination of simultaneous magnetic resonance
imaging (MRI) and radiotherapy delivery. “MRI-guided radiotherapy
has great potential, and we believe ViewRay has the technology and
the team to bring it to fruition,” said Ralf Schnell, CEO, Siemens
Venture Capital.
“We are pleased to welcome SVC to our team, adding to the
technology partnership with the Siemens MR business unit of Siemens
AG,” said Gregory M. Ayers, MD, PhD, ViewRay president and CEO.
“The continuing commitment of our present investors is a testament
to both the significant progress we have made in development of our
system and the overall promise of MRI-guided radiotherapy.”
* At this time, the ViewRay system is for nonclinical research
use only. The Siteman Cancer Center at Barnes-Jewish Hospital and
Washington University School of Medicine in St. Louis, Missouri,
will soon become the first in the world to test the ViewRay
system.
About ViewRay
ViewRay, Inc., of Cleveland, Ohio, is a privately held medical
device company developing advanced radiation therapy technology for
the treatment of cancer. Using MRI-guided radiotherapy, the ViewRay
system is intended to provide continuous soft-tissue imaging during
treatment. The system is being designed so that
clinicians—for the first time—will be able to see where
the actual radiation do
‘/>”/>
